Abstract
Title Initial Experience in Validation of a Telemedicine Risk Assessment Tool for Hospitalization of Patients with COVID-19
Importance Risk assessment of patients with acute coronavirus disease 2019 (COVID-19) in a telemedicine context is not well described. In the setting of large numbers of patients, a risk assessment tool may guide resource allocation not only for patient care but also for maximum healthcare and public health benefit.
Objective To determine whether a risk prediction tool developed and implemented in March 2020 (“COVID-19 Telemedicine Risk Tier Assessment”) accurately predicts subsequent hospitalizations.
Design Retrospective cohort study, enrollment from March 24 to May 26, 2020 with follow-up calls until hospitalization or clinical improvement (final call date range March 27 to June 19, 2020)
Setting Single center “Virtual Outpatient Management Clinic” (VOMC) assessing and managing outpatients from a large quaternary medical system in Atlanta, Georgia
Participants 496 patients with COVID-19 confirmed by nasopharyngeal sampling in isolation at home at the time of diagnosis. Exclusion criteria included: (1) hospitalization prior to VOMC enrollment, (2) immediate discharge from VOMC with no follow-up calls due to resolution.
Exposure Acute COVID-19 illness
Main Outcome and Measures Hospitalization was the outcome. Days to hospitalization was the metric. Survival analysis using Cox regression was used to determine factors associated with hospitalization.
Results The risk-assessment rubric assigned 496 outpatients to tiers as follows: Tier 1, 237 (47.8%); Tier 2, 185 (37.3%); Tier 3, 74 (14.9%). Subsequent hospitalizations numbered 3 (1%), 15 (7%), and 17 (23%) and for Tiers 1-3, respectively. From a Cox regression model with age ≥ 60, gender, and self-reported obesity as covariates, the adjusted hazard ratios using Tier 1 as reference were: Tier 2 HR=3.74 (95% CI, 1.06-13.27; P=0.041); Tier 3 HR=10.87 (95% CI, 3.09-38.27; P<0.001). Tier was the strongest predictor of time to hospitalization.
Conclusions and Relevance A telemedicine risk assessment tool prospectively applied to an outpatient population with COVID-19 identified both low-risk (Tier 1) and high-risk (Tier 3) patients with better performance than individual risk factors alone. This approach may be appropriate for optimum allocation of resources.
Competing Interest Statement
Dr. G. O'Keefe served on an advisory board of Eyepoint Pharmaceuticals in 2019. It is unrelated to the current work.
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Emory IRB STUDY00000766
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Phone: 404-778-5373, Email: jbokeef{at}emory.edu, Address: Emory Clinic A, 1365 Clifton Road NE Atlanta, GA 30322, USA.
Phone: 404-778-1209, Email: etong{at}emory.edu
Phone: 404-315-8889, Email: ttaylor47{at}mac.com
Phone: 404-778-3056, Email: g.d.okeefe{at}emory.edu
Phone: 404-778-7334, Email: dtong{at}emory.edu
Data Availability
Data is not available in de-identified form for distribution at this time.
